Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 2,431 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 2,431 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of C$6.67, for a total transaction of C$16,212.34.

Rostislav Christov Raykov also recently made the following trade(s):

• On Wednesday, September 4th, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$7.45, for a total transaction of C$18,115.81.

Fennec Pharmaceuticals Stock Up 1.8 %

Shares of FRX stock traded up C$0.11 during trading on Friday, reaching C$6.26. The company’s stock had a trading volume of 13,145 shares, compared to its average volume of 1,787. The business has a fifty day moving average price of C$7.52 and a 200-day moving average price of C$9.84. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The company has a market cap of C$171.27 million, a price-to-earnings ratio of 68.33 and a beta of 0.26. Fennec Pharmaceuticals Inc. has a one year low of C$6.14 and a one year high of C$15.43.

Fennec Pharmaceuticals (TSE:FRX) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.08 by C($0.35). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. The firm had revenue of C$9.94 million for the quarter, compared to the consensus estimate of C$18.67 million. Analysts anticipate that Fennec Pharmaceuticals Inc. will post 0.6025751 earnings per share for the current year.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.